These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 16924166

  • 21. Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients.
    Zanchetti A.
    Blood Press Suppl; 2004 Oct; 1():17-32. PubMed ID: 15587108
    [Abstract] [Full Text] [Related]

  • 22. Nationwide efficacy-safety study of nebivolol in mildly hypertensive patients.
    Cleophas TJ, Agrawal R, Lichtenthal A, Mäkel W, Fici F.
    Am J Ther; 2006 Oct; 13(3):192-7. PubMed ID: 16772759
    [Abstract] [Full Text] [Related]

  • 23. Effect of nebivolol and metoprolol treatments on serum asymmetric dimethylarginine levels in hypertensive patients with type 2 diabetes mellitus.
    Oğuz A, Uzunlulu M, Yorulmaz E, Yalçin Y, Hekim N, Fici F.
    Anadolu Kardiyol Derg; 2007 Dec; 7(4):383-7. PubMed ID: 18065333
    [Abstract] [Full Text] [Related]

  • 24. Evolving mechanisms of action of beta blockers: focus on nebivolol.
    Mason RP, Giles TD, Sowers JR.
    J Cardiovasc Pharmacol; 2009 Aug; 54(2):123-8. PubMed ID: 19528811
    [Abstract] [Full Text] [Related]

  • 25. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure).
    van Veldhuisen DJ, Cohen-Solal A, Böhm M, Anker SD, Babalis D, Roughton M, Coats AJ, Poole-Wilson PA, Flather MD, SENIORS Investigators.
    J Am Coll Cardiol; 2009 Jun 09; 53(23):2150-8. PubMed ID: 19497441
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis.
    Van Bortel LM, Fici F, Mascagni F.
    Am J Cardiovasc Drugs; 2008 Jun 09; 8(1):35-44. PubMed ID: 18303936
    [Abstract] [Full Text] [Related]

  • 27. Comparison of Nebivolol monotherapy versus Nebivolol in combination with other antihypertensive therapies for the treatment of hypertension.
    Papademetriou V.
    Am J Cardiol; 2009 Jan 15; 103(2):273-8. PubMed ID: 19121451
    [Abstract] [Full Text] [Related]

  • 28. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart.
    Rozec B, Erfanian M, Laurent K, Trochu JN, Gauthier C.
    J Am Coll Cardiol; 2009 Apr 28; 53(17):1532-8. PubMed ID: 19389564
    [Abstract] [Full Text] [Related]

  • 29. Beneficial effects of switching from beta-blockers to nebivolol on the erectile function of hypertensive patients.
    Doumas M, Tsakiris A, Douma S, Grigorakis A, Papadopoulos A, Hounta A, Tsiodras S, Dimitriou D, Giamarellou H.
    Asian J Androl; 2006 Mar 28; 8(2):177-82. PubMed ID: 16491268
    [Abstract] [Full Text] [Related]

  • 30. EVOLVE (nebivolol evaluation for efficacy and safety in the treatment of hypertension) postmarketing surveillance study.
    Faruqui AA.
    J Indian Med Assoc; 2007 May 28; 105(5):272, 274, 276-7. PubMed ID: 17915798
    [Abstract] [Full Text] [Related]

  • 31. Placebo-controlled comparison of the effects of nebivolol and low-dose hydrochlorothiazide as monotherapies and in combination on blood pressure and lipid profile in hypertensive patients.
    Lacourcière Y, Arnott W.
    J Hum Hypertens; 1994 Apr 28; 8(4):283-8. PubMed ID: 8021909
    [Abstract] [Full Text] [Related]

  • 32. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide.
    Gupta S, Wright HM.
    Cardiovasc Ther; 2008 Apr 28; 26(3):189-202. PubMed ID: 18786089
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial.
    Grassi G, Trevano FQ, Facchini A, Toutouzas T, Chanu B, Mancia G.
    Blood Press Suppl; 2003 Dec 28; 2():35-40. PubMed ID: 14761075
    [Abstract] [Full Text] [Related]

  • 34. Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker.
    Prisant LM.
    J Clin Pharmacol; 2008 Feb 28; 48(2):225-39. PubMed ID: 18083889
    [Abstract] [Full Text] [Related]

  • 35. Nebivolol: new indication. Heart failure: 'me-too' available in single dose strength only. Select better-assessed betablockers.
    Prescrire Int; 2007 Dec 28; 16(92):235. PubMed ID: 18087800
    [No Abstract] [Full Text] [Related]

  • 36. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study.
    Tzemos N, Lim PO, MacDonald TM.
    Circulation; 2001 Jul 31; 104(5):511-4. PubMed ID: 11479245
    [Abstract] [Full Text] [Related]

  • 37. Nebivolol for the treatment of heart failure.
    Riva N, Lip GY.
    Expert Opin Investig Drugs; 2011 Dec 31; 20(12):1733-46. PubMed ID: 21980961
    [Abstract] [Full Text] [Related]

  • 38. Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation.
    Weiss R.
    Vasc Health Risk Manag; 2006 Dec 31; 2(3):303-8. PubMed ID: 17326335
    [Abstract] [Full Text] [Related]

  • 39. Differential effects of nebivolol and atenolol on transmitral diastolic filling parameters in patients with essential hypertension.
    Tuncer M, Guntekin U, Gunes Y, Gumrukcuoglu HA, Eryonucu B.
    Adv Ther; 2008 Jun 31; 25(6):619-26. PubMed ID: 18563311
    [Abstract] [Full Text] [Related]

  • 40. Nebivolol: impact on cardiac and endothelial function and clinical utility.
    Toblli JE, DiGennaro F, Giani JF, Dominici FP.
    Vasc Health Risk Manag; 2012 Jun 31; 8():151-60. PubMed ID: 22454559
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.